Original Report

BRCA1/2 testing and cancer risk management in underserved women at a public hospital


 

Background and objective Genetic test uptake and cancer risk management have been understudied in medically underserved populations. Study aims were to quantify rates of BRCA1/2 genetic testing and evidence-based cancer risk management (ie, prophylactic surgeries and surveillance practices) in women who were seen for breast and ovarian cancer genetic counseling in a public, safety net health system.

Methods We conducted a retrospective medical record abstraction of 195 women who presented for breast or ovarian genetic counseling within a 2-year period (2008-2009) at Parkland Health & Hospital System in Dallas, Texas.

Results The identified women represented a racially and ethnically diverse population: 48% Hispanic, 37% non-Hispanic black, 12% non-Hispanic white, and 3% Asian. Among the 158 women who were medically eligible for genetic testing, 134 (84.8%) received BRCA1/2 results, with most tests funded through a financial assistance program. In all, 29 women (22%) tested positive for BRCA1/2 mutations. Financial and funding barriers were identified for 20 of the untested women. Among the identified high-risk women (mutation carriers, selected variants, and noncarriers with pretest BRCAPRO scores 30 or more), 26% had prophylactic breast surgeries and 33% had prophylactic ovarian surgeries within the follow-up period averaging 35 months. Of those who opted for surveillance, 71% had at least 1 mammogram or MRI and 38% had CA-125 tests. Trends indicated lower rates of all risk management behaviors, except for mammogram or MRI, among non-Hispanic black women.

Conclusions Within this racially and ethnically diverse sample, BRCA1/2 test uptake was high, but financial barriers were identified for nontested women. The rates of breast cancer risk management were generally comparable with other studies, but risk management for ovarian cancer was limited, especially among non-Hispanic black women. The reasons for these apparen disparities should be further explored.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

ASCO: Stop Underdosing Obese Cancer Patients
Breast Cancer ICYMI
Evidence Suggests Pregnancies Can Survive Maternal Cancer Treatment
Breast Cancer ICYMI
Fertility Preservation No Longer Experimental for Cancer Patients
Breast Cancer ICYMI
FDA Warns of QT Prolongation with Ondansetron Dose
Breast Cancer ICYMI
FDA Approves REMS for Long-Acting Opioids
Breast Cancer ICYMI
Washington Post Blasts Proliferation of ESAs for Anemia
Breast Cancer ICYMI
Radiation Oncologists Say Medicare Cuts Could Shutter Practices
Breast Cancer ICYMI
Pregnancy-Related Cancers: Rise Is Largely Unrelated to Delayed Childbearing
Breast Cancer ICYMI
ASRM: Egg Freezing No Longer 'Experimental'
Breast Cancer ICYMI
Is there a relationship between in vitro fertilization and breast cancer?
Breast Cancer ICYMI